Our columnists crack open the murky world of finance and investments
This has been a busy year for investment trust launches. James Carthew looks at some of the new offerings that haven't received the fanfare afforded to Woodford Patient Capital.
The Greek debt crisis is urgent but containable, we're told. But if risk is back 'on' after this weekend, perhaps investors have bigger worries?
Too many UK equity income funds have faith in GlaxoSmithKline's ability to maintain its dividend, says a healthcare investor.
The sell-off in the bond markets has focused my mind on how much debt some of my stocks are carrying. It's time for one of them to go.
Litigation finance fund tumbles after a negative US Supreme Court ruling. But are the shares as cheap as they appear?
After a series of changes in recent year the real estate investment trust looks to be back on track, says James Carthew.
Experienced private investor David Kempton is struggling to find anything to buy in difficult markets, apart from UK house builders.
The pioneering emerging markets investment trust has underperformed its index for the past five years. Has it passed its sell-by date?
I can't 'buy on the dips' because I'm fully invested, and switching from 'defensives' into 'cyclicals' doesn't make sense. What can I do?
Our weekly roundup shows Tim Russell's Sanditon trust looking reasonable value for the first time since its launch a year ago.
How will our novice fare on the markets?
Dumb Investor: 'If I do lose it all in some kind of Madoff-style scam... at least my humiliation will be public.'
Dumb Investor's latest articles
Investment Trust Insider
James Carthew shares his expert knowledge to give you the inside track on investment trusts.